Ariad's 3Q Loss Widens Slightly On Costs
CAMBRIDGE, Mass. (AP) Drug developer Ariad Pharmaceuticals Inc. said Thursday its third-quarter loss widened slightly on overall costs as it continues developing potential cancer treatments.
The company reported a loss of $20.8 million, or 21 cents per share, compared with a loss of $20 million, or 29 cents per share, a year earlier. The company had fewer shares outstanding in the same period a year ago. Revenue rose 40 percent, to $2.2 million from $1.5 million. Analysts polled by Thomson Financial expected a loss of 18 cents per share on revenue of about $2.6 million. The company's lead product candidates include the cancer treatment ridaforolimus, which is being developed in a partnership with Merck & Co. Shares of Ariad closed at $1.98 Thursday.- Loading Comments...
- Loading Comments...
Recent Comments
Featured Photo Galleries
Connect with TheStreet
 |
 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,309.92 | 1,091.49 | 2,138.44 | 32.31 |
Oil *
77.12
|
|
DOWN
154.48
|
DOWN
19.14
|
DOWN
37.61
|
DOWN
0.48
|
10 Yr
3.23%
SPDR Gold
115.06
|
|
-1.48%
|
-1.72%
|
-1.73%
|
-1.46%
|
Data delayed 20 minutes |
